Safety, immunogenicity, and efficacy of Borrelia burgdorferi outer surface protein A (OspA) vaccine: A meta-analysis | Zendy

Hua Zhao | Zendy; Fukai Bao | Zendy; Aihua Liu | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Safety, immunogenicity, and efficacy of Borrelia burgdorferi outer surface protein A (OspA) vaccine: A meta-analysis

Author(s) -

Hua Zhao,

Fukai Bao,

Aihua Liu

Publication year - 2017

Publication title -

the journal of infection in developing countries

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.322

H-Index - 49

eISSN - 2036-6590

pISSN - 1972-2680

DOI - 10.3855/jidc.7999

Subject(s) - immunogenicity , borrelia burgdorferi , borrelia , medicine , vaccination , reactogenicity , titer , virology , lyme disease , antibody titer , vaccine efficacy , lyme , population , immunology , antibody , environmental health

Lyme borreliosis, caused by Borrelia burgdorferi sensu stricto in the United States and by several Borrelia species in Europe and Asia, has a great impact on the health of the global population. There are human vaccines available, such as the outer surface protein A (OspA) vaccine, but still more evidence is needed to verify its function. We investigated the safety, immunogenicity, and efficacy of adjuvanted or non-adjuvanted vaccines containing protective epitopes from Borrelia species OspA serotypes in healthy adults.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research